NCT07656727Phase 2Active not recruiting

A Phase 2 Study to Evaluate the Pharmacodynamics, Safety and Tolerability of BGE-102 in Participants With Obesity and Cardiovascular Risk Factors

Compare the available registry edits below. Primary completion is the date data collection ends for the main study measures; it does not tell you when results will be published.

Open ClinicalTrials.gov record CSV export · Pro

Primary completion2026-11-30Estimated

Enrollment · participants160Estimated

Source updated2026-09-10Last update listed in the registry record

Version history

Changes to this trial

Last 12 months

Pro unlocks the full available history and CSV export. View Pro features

Posted 2026-09-10 · 1 field changed

Recruitment status changed

− Before

~~Recruiting~~

+ After

Active not recruiting

Check registry source

Study details

Conditions studied

Obesity and Cardiovascular Risk

Treatments or interventions studied

Oral BGE-102Drug
Oral Placebo Matching BGE-102Drug

Primary outcomes · main study measures

Read the study measures

measure: Percent change in hsCRP (Dose A); description: Percent change in hsCRP of the BGE-102 Dose A daily compared to Placebo; timeFrame: Week 12; measure: Percent change in hsCRP (Dose B); description: Percent change in hsCRP of the BGE-102 Dose B daily compared to Placebo; timeFrame: Week 12; measure: Percent change in hsCRP (Dose C); description: Percent change in hsCRP of the BGE-102 Dose C daily compared to Placebo; timeFrame: Week 12

History coverage

Research sample: selected versions from May 2023 onward plus a preceding baseline where available. Only selected fields were retained; endpoint measures were truncated to 300 characters. This is not complete trial or sponsor history. Daily snapshots begin when collection starts.

How to read this history